SciClone, Sigma-Tau cancer, infectious news

SciClone appointed to its seven-member board three new board members from shareholder Sigma-Tau, including the company's CEO Gregg Lapointe; head of clinical research II-worldwide drug development Roberto Camerini; and an independent director Trevor Jones. The appointments are part of a settlement between the companies to prevent a director election contest at SciClone's 2009 annual meeting, which is scheduled to be held on or before June 15. Sigma-Tau owns 21.3% of SciClone's outstanding shares. ...